142992-72-1

Usage

Uses

Used in Organic Synthesis:
Guanidine, (4-nitrophenyl)-, mononitrate is used as a reagent in organic synthesis for the preparation of a variety of organic compounds. Its high reactivity makes it a valuable component in the creation of diverse chemical products.
Used in Pharmaceutical Production:
Guanidine, (4-nitrophenyl)-, mononitrate serves as a precursor in the production of pharmaceuticals, contributing to the development of new medications and therapeutic agents.
Used in Agrochemical Production:
Guanidine, (4-nitrophenyl)-, mononitrate is also utilized as a precursor in the manufacturing of agrochemicals, playing a role in the creation of products designed to enhance agricultural productivity and crop protection.
It is crucial to handle Guanidine, (4-nitrophenyl)-, mononitrate with caution due to its potentially hazardous nature, ensuring safety in its application across different industries.

Upstream product

• 420-04-2 CYANAMID 
• 15873-51-5 4-nitroaniline hydrochloride 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 136436-76-5 C₁₃H₁₆N₄O₆ 
• 1215292-27-5 2-(4-nitroanilino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-one 
• 677752-97-5 4-{4-[2-(4-nitro-phenylamino)-pyrimidin-4-yl]-benzenesulfonyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 181065-58-7 N-(4-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine 
• 136437-14-4 C₁₁H₁₂N₄O₆ 
• 136437-16-6 C₂₃H₂₀N₄O₆ 

Relevant academic research and scientific papers

7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones designed by a “cut and glue” strategy are dual aurora a/vegf-r kinase inhibitors

Although overexpression and hyperactivity of protein kinases are causative for a wide range of human cancers, protein kinase inhibitors currently approved as cancer drugs address only a limited number of these enzymes. To identify new chemotypes addressing alternative protein kinases, the basic structure of a known PLK1/VEGF-R2 inhibitor class was formally dissected and reassembled. The resulting 7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones were synthesized and proved to be dual inhibitors of Aurora A kinase and VEGF receptor kinases. Crystal structures of two representatives of the new chemotype in complex with Aurora A showed the ligand orientation in the ATP binding pocket and provided the basis for rational structural modifications. Congeners with attached sulfamide substituents retained Aurora A inhibitory activity. In vitro screening of two members of the new kinase inhibitor family against the cancer cell line panel of the National Cancer Institute (NCI) showed antiproliferative activity in the single-digit micromolar concentration range in the majority of the cell lines.

A novel series of potent and selective IKK2 inhibitors

A novel series of aminopyrimidine IKK2 inhibitors have been developed which show excellent in vitro inhibition of this enzyme and good selectivity over the IKK1 isoform. The relative potency and selectivity of these compounds has been rationalized using QSAR and structure-based modelling.

2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity

Following the identification through virtual screening of 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analogue program was initiated. The first aims were to optimize potency and to evaluate the cellular mode of action of lead candidate molecules. Here the synthetic chemistry, the structure-guided design approach, and the structure-activity relationships (SARs) that led to the discovery of 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors, many with very low nM Kis against CDK2, are reported. Furthermore, X-ray crystal structures of four representative analogues from our chemical series in complex with CDK2 are presented, and these structures are used to rationalize the observed biochemical SARs. Finally results are reported that show, using the most potent CDK2 inhibitor compound from the current series, that the observed antiproliferative and proapoptotic effects are consistent with cellular CDK2 and CDK9 inhibition.

N-phenyl-4-pyrazolo[1,5-6]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy

Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b] pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to an N-phenyl-2-pyrimidine-amine derivative showing a superior effect on tumor, lung cancer, gastric cancer, etc. of warm-blooded animals and its salt. The present invention also relates to a process for preparing the compound and a pharmaceutical composition for the prevention and treatment of such diseases as tumor, lung cancer, gastric cancer, etc., which comprises the compound as an active ingredient.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to an N-Phenyl-2-pyrimidine-aminine derivative showing a superior effect on lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or accute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer or cervical cancer, etc. of warm blooded animals and its salt. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various disease, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.

N-PHENYL-N,N"-GUANIDINEDICARBOXYLIC ACID ESTERS. SYNTHESIS, ANTHELMINTIC AND PESTICIDAL EFFECTS

Substituted phenylammonium chlorides react with cyanamide to give the corresponding phenylguanidines which on treatment with chloroformate esters give N-subst.phenyl-N,N''-guanidinedicarboxylic acid esters.All substances prepared have been tested for their anthelmintic activity against the model helminths Nippostrongylus brasiliensis and Hymenolepis nana var. fraterna.The most significant activity has been found with diethyl N-(4-nitrophenyl)-N,N''-guanidinedicarboxylate.In pesticidal screening the compounds have shown fungicidal activity and particularly ovicidal activity against Tetranychus urticae which activity is increased with the compounds having a nitro group in the benzene ring.